214 related articles for article (PubMed ID: 29258858)
1. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers.
Lee B; Hutchinson R; Wong HL; Tie J; Putoczki T; Tran B; Gibbs P; Christie M
Semin Cancer Biol; 2018 Oct; 52(Pt 2):241-252. PubMed ID: 29258858
[TBL] [Abstract][Full Text] [Related]
2. Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.
Passiglia F; Caglevic C; Giovannetti E; Pinto JA; Manca P; Taverna S; Listì A; Gil-Bazo I; Raez LE; Russo A; Rolfo C
Semin Cancer Biol; 2018 Oct; 52(Pt 2):259-268. PubMed ID: 29391205
[TBL] [Abstract][Full Text] [Related]
3. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
Chen K; Ye H; Lu XJ; Sun B; Liu Q
Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
[TBL] [Abstract][Full Text] [Related]
4. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
Osipov A; Saung MT; Zheng L; Murphy AG
J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
[TBL] [Abstract][Full Text] [Related]
5. Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases.
Xiang Z; Yu Y
Front Med; 2019 Feb; 13(1):24-31. PubMed ID: 30659409
[TBL] [Abstract][Full Text] [Related]
6. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.
Curigliano G
Semin Cancer Biol; 2018 Oct; 52(Pt 2):253-258. PubMed ID: 29775688
[TBL] [Abstract][Full Text] [Related]
7. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.
Gevaert T; Montironi R; Lopez-Beltran A; Van Leenders G; Allory Y; De Ridder D; Claessens F; Kockx M; Akand M; Joniau S; Netto G; Libbrecht L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):216-227. PubMed ID: 29032188
[TBL] [Abstract][Full Text] [Related]
8. Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy.
Zhang M; Yang J; Hua W; Li Z; Xu Z; Qian Q
Front Med; 2019 Feb; 13(1):32-44. PubMed ID: 30680606
[TBL] [Abstract][Full Text] [Related]
9. Emerging targets in cancer immunotherapy.
Burugu S; Dancsok AR; Nielsen TO
Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
[TBL] [Abstract][Full Text] [Related]
10. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.
Li X; Song W; Shao C; Shi Y; Han W
Cell Mol Immunol; 2019 Jan; 16(1):28-39. PubMed ID: 30002451
[TBL] [Abstract][Full Text] [Related]
11. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy: A need for peripheral immunodynamic monitoring.
Wang W; Xia X; Wu S; Guo M; Lie P; He J
Am J Reprod Immunol; 2018 Jun; 79(6):e12793. PubMed ID: 29288509
[TBL] [Abstract][Full Text] [Related]
13. The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.
Butterfield LH
Semin Cancer Biol; 2018 Oct; 52(Pt 2):12-15. PubMed ID: 28943324
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
16. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
17. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Older Adults: A Checkpoint to Palliation?
Elias R; Odejide O
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e110-e120. PubMed ID: 31099630
[TBL] [Abstract][Full Text] [Related]
19. DNA Damage and Repair Biomarkers of Immunotherapy Response.
Mouw KW; Goldberg MS; Konstantinopoulos PA; D'Andrea AD
Cancer Discov; 2017 Jul; 7(7):675-693. PubMed ID: 28630051
[TBL] [Abstract][Full Text] [Related]
20. Delivery Strategies for Immune Checkpoint Blockade.
Chen Q; Wang C; Chen G; Hu Q; Gu Z
Adv Healthc Mater; 2018 Oct; 7(20):e1800424. PubMed ID: 29978565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
